Tirzepatide, a dual GIP/GLP-1 agonist, has shown even greater weight loss than semaglutide in clinical trials
Those most at risk include vegans and vegetarians, people with digestive conditions such as Crohn's disease, coeliac disease or IBS, those taking long-term metformin or proton pump inhibitors, older adults whose ability to absorb B12 through the gut declines naturally with age, those with pernicious anaemia, and anyone with a history of chronic alcohol use
Middle ground for early reactions
In each case, a provider should confirm a deficiency before starting treatment
The real-world implications are significant
Regulates blood sugar by triggering insulin release after meals